After Reaching Milestone, Is ARGOS THERAPEUTICS INC (OTCMKTS:ARGS)’s Short Interest Revealing Something?

May 16, 2018 - By wolcottdaily

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Logo

Investors sentiment increased to 0.85 in Q4 2017. Its up 0.22, from 0.63 in 2017Q3. It improved, as 8 investors sold Argos Therapeutics, Inc. shares while 5 reduced holdings. 6 funds opened positions while 5 raised stakes. 2.48 million shares or 6.25% less from 2.64 million shares in 2017Q3 were reported.
State Street stated it has 0% in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Two Sigma Secs Limited Liability Com holds 47,961 shares. Virtu Finance Lc owns 112,208 shares or 0% of their US portfolio. Deutsche Comml Bank Ag owns 36 shares for 0% of their portfolio. Blackrock Incorporated reported 0% of its portfolio in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Credit Suisse Ag holds 0% or 20,074 shares. Stifel Corporation holds 66,550 shares. Keybank Association Oh stated it has 119,515 shares. Vanguard Grp Inc has 0% invested in Argos Therapeutics, Inc. (OTCMKTS:ARGS) for 1.05 million shares. Royal Financial Bank Of Canada owns 1,351 shares. Northern Corp has invested 0% of its portfolio in Argos Therapeutics, Inc. (OTCMKTS:ARGS). Bankshares Of Ny Mellon Corporation stated it has 0% of its portfolio in Argos Therapeutics, Inc. (OTCMKTS:ARGS). California Employees Retirement Sys has 94,800 shares. Wasatch Advsr Inc accumulated 643,265 shares. Meeder Asset Inc accumulated 0% or 22,439 shares.

The stock of ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) registered a decrease of 91.01% in short interest. ARGS’s total short interest was 65,500 shares in May as published by FINRA. Its down 91.01% from 728,400 shares, reported previously.

The stock decreased 9.43% or $0.018 during the last trading session, reaching $0.172. About 67,166 shares traded. Argos Therapeutics, Inc. (OTCMKTS:ARGS) has declined 87.69% since May 16, 2017 and is downtrending. It has underperformed by 99.24% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $1.82 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.